Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced dosing of the first subjects in a Phase 1 randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) trial of its lead product candidate MET409. ... READ MORE
Metacrine Completes $65 Million Series C Financing
June 6, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C financing which raised $65 million in new funds. ... READ MORE
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
May 31, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today presented data showing equivalent efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist for the potential treatment of inflammatory bowel disease (IBD), to anti-IL-12/23, a biologic agent ... READ MORE
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT (12:30 p.m. PDT) in New York City. ... READ MORE
Metacrine Broadens Management Team with Two Key Hires
April 17, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced two new key management appointments ... READ MORE
Metacrine to Present at 30 th Annual ROTH Conference
March 7, 2018San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced that Ken Song, MD, President and CEO, will give a corporate presentation and participate in a NASH panel discussion at the 30th Annual ROTH Conference ... READ MORE
Metacrine Completes Series B Financing to Advance Best-in-Class FXR Program into Clinical Development
December 7, 2017San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development, today announced it has closed a $22M Series B financing led by new investor New Enterprise Associates (NEA) ... READ MORE
Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.
October 10, 2017San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Washington, D.C. ... READ MORE
Metacrine Announces Collaboration on Development of FGF1 Variants for Glucose Lowering and Improving Insulin Sensitivity
August 15, 2017San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 (“FGF1”) variants for glucose lowering and insulin sensitization. ... READ MORE
Metacrine to Present Two Abstracts on its Novel FXR Non-Bile Acid Agonist Program at the EASL International Liver Congress 2017
April 11, 2017San Diego, CA - Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European Association for the Study of Liver Disease (EASL) in Amsterdam, Netherlands. Metacrine has developed a leading and comprehensive FXR agonist program based on a unique non-bile acid chemical scaffold ... READ MORE
Metacrine Expands Patent Portfolio for Novel FGF-1 Program to Treat Diabetes
October 17, 2016San Diego, CA - Metacrine, Inc., a leading biotechnology company efficiently developing innovative drugs for metabolic diseases, announced the issuance of a new patent by the U.S. Patent and Trademark Office that supports development for the company’s FGF-1 program ... READ MORE
Metacrine Announces Appointment of Dr. Ken Song as President and Chief Executive Officer
September 14, 2016San Diego, CA - Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and director ... READ MORE
Metacrine Raises $36 Million in Series A Financing
August 5, 2015San Diego, CA - Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing... READ MORE